Nurix Therapeutics Announces Positive Phase 1 Trial Results

The latest update is out from Nurix Therapeutics ( (NRIX) ).

On June 12, 2025, Nurix Therapeutics announced positive clinical data from its Phase 1 trial of bexobrutideg (NX-5948) at the European Hematology Association Congress. The data showed an objective response rate of 80.9% in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and 84.2% in patients with Waldenström macroglobulinemia (WM), with bexobrutideg demonstrating a favorable safety profile and potential as a treatment for patients with high unmet medical needs. The company plans to initiate pivotal trials in 2025, reinforcing its scientific leadership in targeted protein degradation.

The most recent analyst rating on (NRIX) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Nurix Therapeutics stock, see the NRIX Stock Forecast page.

Spark’s Take on NRIX Stock

According to Spark, TipRanks’ AI Analyst, NRIX is a Neutral.

The overall score reflects significant financial performance challenges and a weak valuation, tempered by positive corporate developments and some technical momentum. The company’s strong equity position and recent board appointment provide some support, but the lack of profitability and cash flow issues remain major concerns.

To see Spark’s full report on NRIX stock, click here.

More about Nurix Therapeutics

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines. The company is advancing a pipeline that includes degraders of Bruton’s tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), with applications in cancer and inflammatory diseases.

Average Trading Volume: 1,011,139

Technical Sentiment Signal: Sell

Current Market Cap: $975.1M

Find detailed analytics on NRIX stock on TipRanks’ Stock Analysis page.